Pharmacyclics Inc (NASDAQ:PCYC)

256.56
Delayed Data
As of Mar 27
 +0.185 / +0.07%
Today’s Change
82.51
Today|||52-Week Range
258.95
+109.84%
Year-to-Date
Biogen Inc, Gilead Sciences, Inc., Amgen, Inc., Celgene Corporation: Are We In A Biot...
Mar 27 / Investing Channel
Pharma Stock Outlook: Let's Make a Deal - Industry Outlook
Mar 17 / Zacks.com
Biotech, Chips Stand Their Ground
Mar 27 / TheStreet.com
Pharma Stock Outlook: Let's Make a Deal - Zacks Analyst Interviews
Mar 17 / Zacks.com
Are We In A Biotech Bubble? You Decide
Mar 27 / Investing Channel
3 Stocks Benefiting From Jaw-Dropping Growth in Specialty Drug Spending
Mar 17 / MotleyFool.com
Biotechs Need to Rest
Mar 27 / TheStreet.com
Why the Bull Isn't Done Running - Video Blog
Mar 16 / Zacks.com
New ETF From BlackRock And Edelman
Mar 26 / Benzinga
Going the extra mile to win a B#21bn deal
Mar 06 / FT.com
3 Stocks Reiterated As A Hold: PCYC, LNKD, PM
Mar 26 / TheStreet.com
AbbVie wins three-way fight over Pharmacyclics
Mar 05 / FT.com
Biotech Stocks Are Selling Off Just Like 2014 -- and That Might Be a Good Thing
Mar 26 / TheStreet.com
AbbVie joins the pharma chain reaction
Mar 05 / FT.com
Backing Away From Biotechs
Mar 25 / TheStreet.com
Vertex climbs on drug approval hopes
Mar 05 / FT.com
Pharmacyclics chief to receive $3.6bn from takeover
Mar 23 / FT.com
Pharmacyclics CEO sees stake value soar
Mar 05 / FT.com
Better Dividend Stock: AbbVie or Gilead Sciences, Inc.?
Mar 23 / MotleyFool.com
Centerview builds record on pharma deals
Mar 05 / FT.com
Confessions of a Value Investor Stuck in a High-Growth Industry
Mar 22 / MotleyFool.com
Abbvie/Pharmacyclics: pay to play
Mar 05 / FT.com
The Zacks Analyst Blog Highlights: Amgen, Regeneron, Nektar, ACADIA and Pharmacyclics...
Mar 19 / Zacks.com
Q&A - why Abbvie had to strike $21bn Pharmacyclics deal
Mar 05 / FT.com
Biotech Stock Roundup: Amgen & Regeneron Shine at ACC, Nektar Drug Disappoints - Anal...
Mar 18 / Zacks.com
Stocks: 5 things to know before the open
Mar 05 / CNNMoney.com
Pharmacyclics' Imbruvica Encourages in a Phase III Study - Analyst Blog
Mar 17 / Zacks.com
China's rubber stamp parliament, AbbVie's acquisition of Pharmacyclics and the origin...
Mar 05 / FT.com
AbbVie to Buy Pharmacyclics: Biotech ETFs to Watch - ETF News And Commentary
Mar 17 / Zacks.com
J&J nears deal for cancer drugmaker
Mar 04 / FT.com

To view my watchlist

Not a member yet?

Sign up now for a free account